Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Laurent

Showing results (1-10 of 148) with videos related to

Pageof 15
Sort By:
Revue De L'Infirmiere|July 17, 2022
[The nurse at the heart of the assistance system for outpatients in the post-cancer period]Gisèle Compaci, Guy Laurent
Bulletin Du Cancer|December 1, 2004
Ceramide : A New Target in Anticancer Research?Jean-Pierre Jaffrezou, Guy Laurent
Bulletin Du Cancer|May 23, 2013
[Anticancer drug adherence]Fabien Despas, Henri Roche, Guy Laurent
Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
Implication of raft microdomains in drug induced apoptosisChristine Bezombes, Guy Laurent, Jean-Pierre Jaffrézou
Molecular Cancer Research : MCR|September 17, 2011
Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectivesChristine Bezombes, Jean-Jacques Fournié, Guy Laurent
Presse Medicale (Paris, France : 1983)|March 6, 2007
[Myelodysplastic syndromes in adults]Odile Beyne-Rauzy, Guy Laurent, Daniel Adoue
Sub-Cellular Biochemistry|June 1, 2002
Ceramide in regulation of apoptosis. Implication in multitoxicant resistanceJean-Pierre Jaffrézou, Guy Laurent, Thierry Levade
Current Cancer Drug Targets|February 16, 2006
Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cellsGuy Leclercq, Marc Lacroix, Ioanna Laïos, et al.
Oncology Letters|October 5, 2016
Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targetsNadège Kindt, Fabrice Journe, Guy Laurent, et al.
FEBS Letters|August 7, 2002
Sphingomyelin content conditions insertion of daunorubicin within phosphatidylcholine monolayersMarie-France Lecompte, Guy Laurent, Jean-Pierre Jaffrézou
Pageof 15

Showing results (1-10 of 148) with videos related to

Sort By:
Pageof 15
Revue De L'Infirmiere|July 17, 2022
[The nurse at the heart of the assistance system for outpatients in the post-cancer period]Gisèle Compaci, Guy Laurent
Bulletin Du Cancer|December 1, 2004
Ceramide : A New Target in Anticancer Research?Jean-Pierre Jaffrezou, Guy Laurent
Bulletin Du Cancer|May 23, 2013
[Anticancer drug adherence]Fabien Despas, Henri Roche, Guy Laurent
Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
Implication of raft microdomains in drug induced apoptosisChristine Bezombes, Guy Laurent, Jean-Pierre Jaffrézou
Molecular Cancer Research : MCR|September 17, 2011
Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectivesChristine Bezombes, Jean-Jacques Fournié, Guy Laurent
Presse Medicale (Paris, France : 1983)|March 6, 2007
[Myelodysplastic syndromes in adults]Odile Beyne-Rauzy, Guy Laurent, Daniel Adoue
Sub-Cellular Biochemistry|June 1, 2002
Ceramide in regulation of apoptosis. Implication in multitoxicant resistanceJean-Pierre Jaffrézou, Guy Laurent, Thierry Levade
Current Cancer Drug Targets|February 16, 2006
Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cellsGuy Leclercq, Marc Lacroix, Ioanna Laïos, et al.
Oncology Letters|October 5, 2016
Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targetsNadège Kindt, Fabrice Journe, Guy Laurent, et al.
FEBS Letters|August 7, 2002
Sphingomyelin content conditions insertion of daunorubicin within phosphatidylcholine monolayersMarie-France Lecompte, Guy Laurent, Jean-Pierre Jaffrézou
Pageof 15